Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention.
Recent experimental and clinical studies have placed new emphasis on the role of the innate immune system in SLE. Nucleic acid-containing immune complexes activate the innate response by engaging specific Toll-like receptors (TLRs) and promote the generation of autoantibodies. Pharmacologic modulation of TLR-directed pathways may offer new therapeutic approaches for the treatment of SLE.
Kim
Wan-Uk
WU
Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul, South Korea. wan725@catholic.ac.kr
Sreih
Antoine
A
Bucala
Richard
R
D000818:Animals; D001323:Autoantibodies / Q000097:blood*; D018899:CpG Islands / Q000276:immunology; D006706:Homeostasis; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology* / Q000628:therapy; D051379:Mice; D017382:Reactive Oxygen Species; D017411:Ribonucleoproteins, Small Nuclear / Q000276:immunology / Q000378:metabolism*; D017634:Self Tolerance; D015398:Signal Transduction / Q000276:immunology; D051199:Toll-Like Receptor 7 / Q000276:immunology / Q000378:metabolism*; D051217:Toll-Like Receptor 9 / Q000276:immunology / Q000378:metabolism*
D001323:Autoantibodies; D016898:Interferon-alpha; D017382:Reactive Oxygen Species; D017411:Ribonucleoproteins, Small Nuclear; D051199:Toll-Like Receptor 7; D051217:Toll-Like Receptor 9